to the lethal action of Cd2+ produced in mice was maintained for 6 to 24 hr after pretreatment with 1/10 of the challenge Cd2+ doses as shown by an increased oral LD50. Pretreatment 24 hr prior to the challenge doses was most effective. In addition, 1/20 to 1/7 of the challenge doses was necessary to acquire the tolerance to the acute oral toxicity of Cd2+. The largest effect was found for pretreatment with 1/7 of the challenge doses. Acute liver injury at 24 hr after challenge with a large dose of Cd2+ (100 mg Cd2+/kg, p.o.) was markedly reduced by pretreatment with a small dose of the cation (15 mg Cd2+/kg, p.o.) 24 or 48 hr prior to the challenge dose as shown by a marked reduction in serum GOT and GPT activities and the reversal of histopathological changes. The elevated serum urea nitrogen at 4 hr after the Cd2+ challenge was reduced by pretreatment 6 to 24 hr prior to the challenge dose. In spite of the increased urea nitrogen 4 hr after the Cd2+ challenge, no morphological alterations were observed in the kidney at 24 hr. Serum Alp activity was not significantly influenced by the Cd2+ challenge. Glucose in serum was increased by the administration of a small dose of Cd2+, but was unaffected by a large dose. Decreases in hepatic RNA and DNA concentrations at 24 hr after the Cd2+ challenge were prevented by pretreatment 24 or 48 hr prior to the challenge dose. Potentiation of hexobarbital sleep time was observed at 6 or 24 hr after a small dose of Cd2+. Nevertheless, further potentiation at 24 hr after the Cd2+ challenge (75 mg Cd2+/kg, p.o., in this case) was reduced by pretreatment 24 hr prior to the challenge dose. A major target organ for the acute oral toxicity of Cd2+ was the liver rather than the kidney.
Pretreatment of animals with small doses of certain metals protects against subsequent toxic doses of the same metals (1) (2) (3) (4) (5) . It has been proposed that protection by Cd2+ pretreatment against a lethal dose of the cation is due to the induction of metallothionein (MT) synthesis (4, 6-8). However, Webb and Verschoyle (3) have suggested that pre-induced MT may not be the only factor giving protection against the toxic action of Cd2+. As these investigations (2-8) were performed by parenteral administration of the test metal, the interaction of the metal with intestinal tissue was not studied.
In my preliminary study (unpublished data), oral LD50 values for cadmium chloride, cupric chloride, ferrous sulfate, ferric chloride, mercuric chloride, manganese chloride, lead nitrate and zinc sulfate were determined in female ICR mice pretreated orally with single small doses (1/10 of the challenge doses) of the same cations or with deionized water 24 hr prior to the challenge doses. Among the eight metal salts tested, Cd2+ pretreatment gave the most effective protection against the acute oral toxicity of the same cation as evidenced by an increased LD50. Therefore, the present study was designed with oral administration of Cd2+ to mice to examine the effects of time intervals between pretreatment and challenge and pretreatment doses on the LD50 values for Cd2+. In addition, the purpose of this study was to investigate the effects of pretreatment with a small oral dose of Cd2+ on blood biochemical parameters, hepatic RNA and DNA concentrations, hepatic drug metabolism and histological changes in mice challenged orally with a large dose of the cation and to determine whether the results obtained correlate with the reduction of the acute oral toxicity of Cd2+ induced by pretreatment with a small dose of Cd2+.
Materials and Methods Animals and treatment: Five to six weekold female mice of the ICR strain (Clea Japan, Inc., Osaka) were used. They were maintained in a room of controlled temperature (23±2°C) and relative humidity (60±10%). Standard laboratory chow (MF, Oriental Yeast Co., Ltd., Osaka) and water were freely available throughout the experiment.
Cadmium chloride dissolved in deionized water was administered to the mice by the oral route.
For determination of LD50, mice were divided into six to ten groups of ten or fifteen animals each. Groups of mice were given different doses of Cd2+ by varying the volume of the solution of a fixed concentration. The dose was increased in a geometric ratio by a factor of 1.25. The solution for challenge administration was diluted 1/80, 1/40, 1/20, 1/10 or 1/7 with deionized water to make the solution for pretreatment. Mice were pretreated with small doses (1/80, 1/40, 1/20, 1/10 or 1/7 of the challenge doses) of Cd2+ at time intervals of 6, 24, 48 or 72 hr prior to the challenge doses of the cation. In the control group, mice were pretreated with the same volume of deionized water instead of the Cd2+ solution. From the mortality data after the challenge doses of Cd2+, the 24-and 168-hr LD50 values were calculated by the method of Bliss (9).
To examine the effects of pretreatment with a small dose of Cd2+on blood biochemical parameters, hepatic RNA and DNA concentrations, hepatic drug metabolism and histological changes in mice challenged 10,000 g for 10 min at 5•Ž, and the 10,000 g supernatant was used as the enzyme preparation. Aminopyrine demethylase was determined by measuring the formation of formaldehyde (17) . Aniline hydroxylase was determined by measuring the quantity of p-aminophenol formed (17) .
Histological examination: After gross necropsy of the major organs, the liver, kidney and small intestine were fixed in formalin. Routine hematoxylin and eosin stains were used for histological examination.
Statistical analysis: Statistical differences between the groups were evaluated by the test for parallelism of two dose-mortality regression lines and the estimate of potency ratio or Student's t-test.
Results
Effect of time intervals between pretreatment and challenge on the oral LD50 for Cd2+: Mice were pretreated with 1/10 of the challenge doses of Cd2+ at time intervals of 6, 24, 48 or 72 hr prior to the challenge doses. Pretreatment 6 or 24 hr prior to the challenge doses protected mice significantly against the acute toxicity of Cd2+ as shown by increased LD50 values. Pretreatment 24 hr prior to the challenge doses was most effective, but the protection was diminished when the Cd2+-pretreated mice were challenged at 72 or more hr later ( the Cd2+-pretreated group with 1/7 of the challenge doses than that with 1/10, suggesting that the protective effect reached nearly maximum (Table 2 , Fig. 2 ). Serum biochemical findings: Serum GOT activity in mice treated with a small dose of Cd2+ (group Cd(S)) was not different from that in the controls (group Aq). In mice challenged with a large dose of Cd2+ (group Aq-Cd(L)), this enzyme activity had not changed 4 hr after the challenge dose, but increased remarkably by 24 hr. The increase in GOT activity 24 hr after the Cd2+ challenge was reduced by pretreatment with a small dose of the cation (group Cd(S)-Cd(L)). Pretreatment 24 or 48 hr prior to the challenge dose was more effective (Table 3) .
Serum GPT activity of mice after treatment with a low dose of Cd2+ increased significantly by 6 hr, but returned to the control level within 24 hr (group Cd(S)). The enzyme activity after the Cd2+ challenge increased somewhat by 4 hr and increased drastically by 24 hr (group Aq-Cd(L)). The elevated GPT activity 24 hr after the Cd2+ challenge was reduced by pretreatment with a small dose of the cation (group Cd(S)-Cd(L)), particularly by pretreatment 24 or 48 hr prior to the challenge dose (Table 4 ). In addition, both GOT and GPT activities 4 hr after the Cd2+ challenge were higher in the Cd2+-pretreated mice 6 hr prior to the challenge dose than in the corresponding water-pretreated animals.
Serum urea nitrogen was unaffected by administration of a low dose of Cd2+ (group Cd(S)). In mice given a high dose of Cd2+ (group Aq-Cd(L)), urea nitrogen increased markedly by 4 hr after administration, but returned to the control level (group Aq) within 24 hr. Pretreatment with a low dose of Cd2+ 6 or 24 hr prior to the challenge dose Table 2 .
Effect of pretreatment doses on the acute oral toxicity of Cd2+ Fig. 2 . Effect of pretreatment doses on the dosemortality regression lines for Cd2+. Mice were pretreated with 1/40, 1/20, 1/10 or 1/7 of the challenge doses of Cd2+ 24 hr prior to the challenge doses which were increased in a geometric ratio by a factor of 1.25. prevented the increase in urea nitrogen induced 4 hr after the Cd2+ challenge (Table 5) .
Serum Alp activity was not influenced in mice treated with a small dose of Cd2+ (group Cd(S)). The decrease in Alp activity induced by a large dose of Cd2+ was not ameliorated by pretreatment with a small dose of the cation (group Cd(S)-Cd(L)), though those changes were within normal ranges (Table 6 ).
Glucose in serum was increased 6 hr after administration of a small dose of Cd2+ and then decreased gradually with time, but was still higher than the control level even at 72 hr (group Cd(S)). With mice challenged with a large dose of Cd2+, the glucose level of the Cd2+-pretreated mice (group Cd(S)-Cd(L)) was higher than that of the waterpretreated animals (group Aq-Cd(L)), which was hardly different from that of the controls (group Aq, Table 7 ).
Effect of Cd2+ on hepatic concentrations of RNA and DNA: Hepatic concentrations of RNA and DNA were unaffected by a small dose of Cd2+ (group Cd(S)), but were decreased by a large dose (group Aq-Cd(L)). Pretreatment with a small dose of Cd2+ 24 or 48 hr prior to the challenge dose inhibited the decrease in the RNA concentration after the challenge dose (group Cd(S)-Cd(L)). Besides, pretreatment 6, 24 or 48 hr prior to the challenge dose prevented the decrease in the DNA concentration after the challenge dose (Tables 8 and 9 ).
Effect of Cd2+ on hexobarbital sleep time:
Hexobarbital sleep time was significantly potentiated at 6 and 24 hr after treatment with a small dose of Cd2+ (group Cd(S)). A marked potentiation in hexobarbital sleep time 24 hr after challenge with a large dose of Cd2+was significantly reduced by pretreatment with a small dose of the cation 24 hr prior to the challenge dose, but little affected by pretreatment at other times prior to the challenge dose (group Cd(S)-Cd(L), Table 10 ).
Effect of Cd2+ on hepatic drug metabolism: Hepatic aminopyrine demethylase and aniline hydroxylase activities tended to be inhibited by administration of a small dose of Cd2+ (group Cd(S)) and more inhibited by a large dose (group Aq-Cd(L)). However, the inhibition of these enzyme activities tended to be reduced by pretreatment 24 hr prior to the challenge dose (group Cd(S)-Cd(L), Table 11 ).
Pathological findings: There were no pathological changes in the liver, kidney and small intestine from mice treated with a small dose of Cd2+ (group Cd(S)). Macroscopically, however, about 1/3 of the livers from mice 24 hr after challenge with a large dose of Cd2+ were abnormal blackish-red in all areas or with yellowish-brown areas on a normal-colored background (group AqCd(L)). Histological examination of these livers revealed degenerative and necrotic changes with congestion. The necrotic areas were scattered mainly near the subcapsular Fig. 3a) . These macroscopic and microscopic observations of the liver were ameliorated by pretreatment with a small dose of Cd2+, particularly by pretreatment 24 hr prior to the challenge dose (group Cd(S)-Cd(L), Fig. 3b ).
On the other hand, the kidney 24 hr after a large dose of Cd2+ showed no significant morphological alterations in the waterpretreated mice (group Aq-Cd(L)) as well as in the Cd2+-pretreated mice (group Cd(S)-Cd(L)), though serum urea nitrogen elevated temporarily by 4 hr after the Cd2+ challenge ( Fig. 3c and 3d) .
The small intestine was grossly dilated and relaxed 4 hr after the Cd2+ challenge, but returned to normal by 24 hr (group AqCd(L)).
These macroscopic changes were ameliorated by pretreatment with a small dose of Cd2+, especially by pretreatment 24 hr prior to the challenge dose (group Cd(S)-Cd(L)).
No pathological changes were observed in the small intestine 24 hr after the Cd2+ challenge.
Discussion
The present study of the oral administration of Cd2+ to mice revealed that protection against the lethal action of the Cd2+ challenge was retained for 6 to 24 hr after pretreatment with 1/10 of the challenge doses as evidenced by increased LD50 values. The largest effect was noted for pretreatment 24 hr prior to the challenge doses.
The protection was diminished when the Cd2+-pretreated mice were challenged 72 or more hr later. In addition, pretreatment of mice with 1/20 to 1/7 of the challenge doses was necessary to acquire the effective protection against the acute toxicity of Cd2+. Pretreatment with 1/7 of the challenge doses was found to be the most effective. Intraperitoneal injection with 1/20 to 1/2 of a lethal dose of Cd2+ is required to protect male mice against a subsequent normally lethal dose of the cation, and the protection is maintained for 3 days by pretreatment with 1/5 of the lethal dose (2). According to Webb and Verschoyle (3), the tolerance to an i.v. lethal dose of Cd2+ produced in rats by a small dose of the cation is maximal 1 to 3 days after pretreatment and then decreases. However, the increased capacity to incorporate Cd2+ into the liver metallothionein (MT) remains constant for 10 days. Therefore, they have suggested that MT does not play a significant role in the protection against the toxic effect of Cd2+. Without distinction of the route of administration, it was confirmed that the tolerance to Cd2+ lethality is acquired several hours after pretreatment with a small dose of the cation and maintained at most for a few days.
There was no sex difference in the acute oral toxicity of Cd2+ for mice pretreated with small doses (1/10 of the challenge doses) of the cation or with deionized water 24 hr prior to the challenge doses. In male mice, the 24-and 168-hr LD50 (95% confidence limits) values of Cd2+ for the Cd2+-pretreated group were 184 (160-211) and 146 (126-170) mg Cd2+/kg, respectively, while those for the water-pretreated group were 109 (96-123) and 98 (87-111) mg Cd27kg, respectively.
In the present study, acute liver injury 24 hr after challenge with a large dose of Cd2+ (100 mg Cd2+/kg, p.o.) was prevented by pretreatment with a small dose of the cation (15 mg Cd27kg, p.o.). The preventive effect of pretreatment was confirmed by a marked reduction of elevated serum GOT and GPT activities and disappearance of degenerative and necrotic changes in the liver. Pretreatment 24 hr prior to the Cd2+ challenge was the most effective. At 4 hr after a large dose of Cd2+, GPT activity had already increased significantly, but GOT activity had not. Thus, GPT was more sensitive to Cd2+ toxicity than GOT. It is known that the former is more specific to the liver than the latter.
Although renal dysfunction was observed at 4 hr after a challenge dose of Cd2+, it had rapidly recovered within 24 hr as indicated by changes in serum urea nitrogen. In spite of the increase in serum urea nitrogen 4 hr after the Cd2+ challenge, there were no morphological changes in the kidney 24 hr after the challenge dose. This increase 4 hr after the Cd2+ challenge was reduced by pretreatment 6 or 24 hr prior to the challenge dose. These histological findings after a large oral dose of Cd2+ are in agreement with those of Hoffmann et al. (18) that ultrastructural damage to the liver, but not to the kidney, have been observed 16 hr after the i.v. administration of Cd2+ to rats. Further, according to Murakami and Webb (19) , throughout the 24-hr experimental period, no morphological changes are observed by light microscopy in the kidney of rats given Cd2+ s.c., although 4 hr after administration of the cation _ together with cysteine, obvious pathological changes appear in the kidney and are progressive with time.
Glucose in the serum was increased by the administration of a small dose of Cd2+, but was unaffected by a large dose. The hyperglycemic effect of Cd2+ involves the adrenals since it is prevented by adrenalectomy (20) . Therefore, the loss of hyperglycemia by a high dose of Cd2+ may be due to adrenal dysfunction.
RNA reflects cell growth and the amount of DNA is related to cell numbers (21) . Thus, the decrease in hepatic RNA and DNA concentrations at a large dose of Cd2+ suggested depression of cell growth and decrease in cell numbers. Pretreatment with a small dose of Cd2+ 24 or 48 hr prior to the Cd2+ challenge protected hepatic cells.
Potentiation of hexobarbital sleep time and inhibition of hepatic drug-metabolizing enzymes have been observed after acute Cd2+ administration to animals (22) (23) (24) (25) . On the contrary, Wagstaff (26) has reported a stimulatory effect of dietary Cd2+ on hepatic microsomal drug metabolism. In the present study, hexobarbital hypnosis was markedly prolonged by a high dose of Cd2+ and also significantly by a low dose. That is, following administration of a low dose of Cd2+, mice became more sensitive to hexobarbital hypnosis in contrast to the reactions of the other parameters examined. Nevertheless, pretreatment with a low dose of Cd2+ 24 hr prior to the challenge dose reduced the potentiation of hexobarbital sleep time by the challenge dose. In addition, the inhibition of both aminopyrine demethylase and aniline hydroxylase after the Cd2+ challenge tended to be reduced by pretreatment. In a study with an i.p. administration of Cd2+ to mice (27) , the protective effect of Cd2+ pretreatment against the inhibition of hepatic drug metabolism by the challenge dose is diminished within 7 days after pretreatment.
Induction of MT synthesis in the liver and kidney has been confirmed as a defense mechanism against exposure to Cd2+ (4, 6-8, 28 ). There is a lag phase of 3 to 4 hr between the parenteral administration of Cd2+ and the onset of MT synthesis in the liver of rats (29) . As pretreatment with Cd2+ not only induces hepatic MT synthesis but also 'primes' the synthetic mechanism , a further synthesis of MT occurs without a lag phase in response to a subsequent exposure to the cation (30) . In the present study, the protection induced by pretreatment with a small dose of Cd2+ against the aggravation of biochemical and histological parameters at a large dose of the cation may be attributed, at least in part, to the presence of MT in the liver and kidney of the Cd2+-pretreated mice. Roberts and Schnell (31) have reported that the time course of MT synthesis induced by an i.p. pretreatment of rats with Cd2+ is not completely consistent with the development of tolerance to the inhibition of hepatic drug metabolism at a subsequent larger dose of the cation. Therefore, they have suggested that factors in addition to MT may play a role in the development of tolerance.
On the whole, the present results obtained from the biochemical and histological parameters correlated with the reduction of the acute oral toxicity of Cd2+ produced by pretreatment with small doses of the cation as shown by increased LD50 values. The liver rather than the kidney was considered to be the target organ for the acute oral lethality of Cd2+. Dudley et al. (32) have recently suggested that death of rats acutely given large i.v. doses of Cd2+ may be due to liver failure.
